Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Bone Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DKK1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DKK1 ECD-Fc / His-Tagged Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View DKK1 Products |
| Gene Delivery | DKK1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional expression. |
View DKK1 Products |
| Benchmark Ab | Anti-DKK1 Recombinant Antibody (Sequence of DKN-01) Recombinant positive control for binding and neutralization assays. |
View DKK1 Products |
| Validator | DKK1 siRNA Set For target knockdown verification and specificity validation. |
View DKK1 Products |
| Related Target A | LRP6 Core receptor interacting with DKK1 to inhibit Wnt signaling. Essential for ligand-receptor blocking assays. |
View LRP6 Products |
| Related Target B | Kremen1 Co-receptor forming a ternary complex with DKK1 and LRP6 to induce receptor internalization. |
View Kremen1 Products |
| Related Target C | DKK2 Subfamily homolog. Crucial for off-target counter-screening to ensure candidate specificity. |
View DKK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ligand-receptor blocking validation | High-purity human LRP6 and Kremen1 extracellular domain proteins available with native mammalian glycosylation. |
| Subfamily off-target counter-screening | Homolog panel (DKK2, DKK4) strictly verified by mass spectrometry and sequence analysis to prevent cross-reactivity. |
| Lack of standardization controls | Recombinant DKN-01 biosimilar benchmark antibody included to establish robust assay baselines. |
| Assay system background noise | Endotoxin-controlled, high-purity (>95% by SDS-PAGE) antigens minimize non-specific binding in SPR/ELISA. |
Live DKK1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DKK1 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies (mAbs) to combination therapies and bispecific modalities. DKK1, a key secreted antagonist of the Wnt/β-catenin signaling pathway, is highly upregulated in various cancers (such as gastric, prostate, and gynecological malignancies) where it suppresses anti-tumor immunity and promotes osteolytic bone metastasis. As first-generation therapies reach late-stage clinical trials, the next wave of R&D is targeting synergistic pathway blockades and bispecific constructs to overcome the immunosuppressive tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Leap Therapeutics, BeiGene | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Neutralization Assay (Requires high-purity, natively glycosylated LRP6 and DKK1 proteins) |
| Bispecific Antibody | Innovent Biologics, Akeso | Solid Tumors, Hepatocellular Carcinoma | Dual-targeting Validation (Requires highly stable, sequence-verified antigen panels) |
| CAR-T / Cell Therapy | Academic institutions, Biotech startups | Multiple Myeloma, Osteosarcoma | Target Expression & Specificity (Requires DKK1 Lentivirus for stable cell line generation) |